Ocugen Gains Provisional Approval for OCU400 in The Bahamas
MALVERN, Pa. — September 25, 2026 Ocugen Inc. announced that its investigational modifier gene therapy OCU400 has received provisional...
inherited retinal disease
Advertisement
Octant Doses First Patient in Phase 1b/2 OCT-980 Study
EMERYVILLE, Calif. — September 24, 2026 Octant, Inc. announced that the first patient has been dosed in the Phase...
Nanoscope’s MOGENRY BLA Accepted by FDA for Retinitis Pigmentosa
Dallas, Texas, USA, September 9, 2026 Nanoscope Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has...
Opus Genetics Advances OPGx-BEST1 Toward Phase 3
RESEARCH TRIANGLE PARK, N.C. — September 9, 2026 Opus Genetics, Inc. announced positive 3- and 6-month data from the...
Seaport Therapeutics Reports Q2 Progress Across Neuropsychiatry Pipeline
BOSTON, Aug. 3, 2026 Seaport Therapeutics, Inc. reported its second-quarter 2026 financial results while highlighting continued progress across its...
Advertisements
Biocon Launches Yesafili Biosimilar to Eylea in U.S.
BENGALURU, India, and BRIDGEWATER, N.J., Aug. 3, 2026 Biocon Limited has announced the U.S. commercial launch of Yesafili™ (aflibercept-jbvf),...
Can-Fite Launches Phase 2 Piclidenoson Trial for Lowe Syndrome
RAMAT GAN, Israel, Aug. 3, 2026 Can-Fite BioPharma Ltd. has launched its first clinical development program evaluating Piclidenoson for...
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
Atsena Selects ATSN-401 for Stargardt Disease
DURHAM, N.C., July 9, 2026 Atsena Therapeutics announced the selection of ATSN-401 as its lead clinical candidate for the...
Opus Genetics Provides BEST1 Phase 1/2 Trial Timeline for OPGx-BEST1 Data
RESEARCH TRIANGLE PARK, N.C., July 9, 2026 Opus Genetics announced an important clinical development update for its Phase 1/2...
Advertisement
